The PRKACA kinase domain was also found to play an essential role in FL-HCC tumor formation, suggesting the potential for small molecule PRKACA-inhibitors as a therapy for FL-HCC (Kastenhuber et al., 2017). Here, PRKACA is linked to hepatocellular carcinoma.